Ç廪´óѧҩѧԺÈÄŸú¿ÎÌâ×éÕÐÆ¸---»¯Ñ§ÉúÎïѧÓëÒ©Îﻯѧ²©Ê¿ºó
±¾ÊµÑéÊÒÖ÷ÒªÖÂÁ¦ÓÚ¿ªÕ¹»ùÓÚµ°°×Öʽµ½â¼¼ÊõµÄ»¯Ñ§ÉúÎïѧÑо¿¼°Ïà¹Ø×ª»¯Ò½Ñ§Ñо¿¡£ ӦƸʱ¼ä£º´Ó2018Äê10ÔÂÆð£¬ÕÐÂúΪֹ¡£ ÕÐÆ¸ÈËÊý£º1-2ÈË
Ñо¿·½Ïò£º¿ªÕ¹»ùÓÚµ°°×Öʽµ½â¼¼ÊõµÄ»¯Ñ§ÉúÎïѧÓëÒ©ÎﻯѧÑо¿¡£
¹ØÓÚµ°°×Öʽµ½â¼¼ÊõµÄÑо¿±³¾°,¿É²Î¿¼ÈÄŸú¿ÎÌâ×é½üÆÚÔÚCell Research·¢±íµÄÑо¿ÂÛÎÄ:¡¶ÀûÓÃÐÂÐ͵°°×ÖʰÐÏò½µ½â¼¼Êõ¿Ë·þIbrutinibÄÍÒ©µÄBϸ°û¶ñÐÔÖ×Áö¡·PROTAC-Induced BTK Degradation as a Novel Therapy for Mutated BTK C481S Induced Ibrutinib-Resistant B-Cell Malignancies
ӦƸÌõ¼þ£º
1. ¶ÔÇ°ÑØÒ©Îï·¢ÏÖ£¬Ïà¹ØÉúÎïѧ»úÖÆÑо¿£¬Ò©Àíѧ»òת»¯Ò½Ñ§¹¤×÷ÓÐÇ¿ÁÒµÄÐËȤ¡£
2. ²©Ê¿Ñо¿±³¾°ÎªÉúÎïѧ£¬Ò©Àíѧ£¬Óлú»¯Ñ§£¬Ò©Îﻯѧ£¬Ò½Ñ§»òÏà¹ØÁìÓò¡£
3. ¹¤×÷×÷·ç»ý¼«¿Ï¸É£¬²¢ÓÐÖ¾ÓÚ½ñºóÔÚҩѧ¼°×ª»¯Ò½Ñ§Ñо¿µÄѧÊõ¿ÆÑÐÁìÓòÓÐËù·¢Õ¹¡£ÓÐÁ¼ºÃµÄÓëÈËÏà´¦ºÍ¹µÍ¨µÄÄÜÁ¦¼°ÍŶӺÏ×÷¾«Éñ¡£
´ýÓö£ºÊµÑéÊÒ½«Îª²©Ê¿ºóÌṩ¸ßˮƽµÄʵÑéÆ½Ì¨¼°¿ÆÑл·¾³£¬ÆäËü´ýÓö°´ÕÕÇ廪´óѧÏà¹Ø¹æ¶¨Ö´ÐУ¨¾ßÌåÇé¿ö²Î¼ûÇ廪´óѧ²©Ê¿ºóÉêÇëÏà¹ØÍøÒ³£©¡£ÓÅÐãµÄÉêÇëÈ˽«ÍƼöÉêÇëÉúÃü¿ÆÑ§ÁªºÏÖÐÐIJ©Ê¿ºó»ù½ð¡£¾ßÌå²Î¼û£ºhttps://www.cls.edu.cn/
ÁªÏµÈË£ºÈÄŸú ÀÏʦ
ÉêÇë²ÄÁÏ£ºÉêÇëÈ˵ĸöÈ˼òÀú¼°ÏêϸµÄ¹¤×÷¾ÀúºÍÑо¿³É¹û£¬²¢Ìṩ1£2Î»ÍÆ¼öÈ˵ÄÐÕÃû¼°ÁªÏµ·½Ê½¡£Ç뽫ÉêÇë²ÄÁÏ·¢ÖÁ£ºraolabthu_1@163.com
·µ»ØÐ¡Ä¾³æ²é¿´¸ü¶à
¾©¹«Íø°²±¸ 11010802022153ºÅ
£¬